Showing 1,268 results

Filters Content type: News, Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Europe approves Gilead's HIV combo Eviplera

Editor's pick
Pharma Times
5 December 2011
New & experimental HIV treatments

Nearly 90 Medicines and Vaccines In Development for HIV/AIDS

Editor's pick
Pharmiweb
1 December 2011
Access to healthcare

Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS

Editor's pick
Press release
1 December 2011
New & experimental HIV treatments

Edurant (rilpivirine) approved in European Union

Editor's pick
Janssen press release
29 November 2011
New & experimental HIV treatments

Gilead Sciences Receives European Marketing Authorization for Eviplera

Editor's pick
Business Wire
28 November 2011
Pharmaceutical industry

Complete One-Pill, Once-Daily Prezista-Based HIV Regimen Enters Development

Editor's pick
AIDSMeds
16 November 2011
Pharmaceutical industry

Gilead and J&J expand HIV cocktail partnership

Editor's pick
CNBC
15 November 2011
New & experimental HIV treatments

Ritonavir dose of 50 mg could be sufficient to boost some protease inhibitors, trials needed

News
15 November 2011
Pharmaceutical industry

DFH Pharma Obtains Exclusive Rights to Second-Generation HIV Maturation Inhibitor Program

Editor's pick
DFH press release
1 November 2011
Pharmaceutical industry

Over the Next Decade, the Dominance of Bristol-Myers Squibb Company 's Atripla in the HIV Drug Market Will Be Challenged by Gilead's Quad and Janssen's Complera

Editor's pick
Business Wire
28 October 2011
Pharmaceutical industry

Gilead posts higher profit, seeks Quad approval

Editor's pick
Reuters
27 October 2011
New & experimental HIV treatments

EACS: Does Maraviroc Intensification Promote Better CD4 Cell Recovery?

Editor's pick
HIVandhepatitis.com
27 October 2011
New & experimental HIV treatments

BMS to develop Reyataz fixed-dose pill with Gilead booster drug

Editor's pick
MarketWatch
26 October 2011
Pharmaceutical industry

Gilead At Crucial Stage For Next-Era HIV Meds

Editor's pick
Investor's Business Daily
19 October 2011
Treatment guidelines

US panel updates antiretroviral treatment guidelines

News
18 October 2011
New & experimental HIV treatments

Switching from efavirenz to rilpivirine single tablet is safe and effective

News
18 October 2011
Hepatitis C treatment

Gene variant that helps hepatitis C treatment may hinder HIV treatment

News
14 October 2011
New & experimental HIV treatments

Raltegravir continues to perform well at four years

News
14 October 2011
New & experimental HIV treatments

Dolutegravir is potent but twice-daily works better for integrase-resistant

News
14 October 2011
New & experimental HIV treatments

Boehringer signs away HIV rights to focus on hep C - InPharm

Editor's pick
InPharm
7 October 2011
Pharmaceutical industry

Gilead Sciences inks licensing deal for HIV drug -

Editor's pick
Bloomberg BusinessWeek
6 October 2011
New & experimental HIV treatments

Behind the headlines: HIV vaccine passes phase I trial

Editor's pick
NHS Choices
30 September 2011
The search for an HIV prevention vaccine

HIV vaccine is a small breakthrough, but not a cure

Editor's pick
The Guardian
29 September 2011
New & experimental HIV treatments

Biotron begins landmark phase 1b/2a human trial for HIV drug

Editor's pick
Business Spectator
29 September 2011